Aktis Oncology (AKTS) News
NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.15-0.25 (-1.52%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AKTS news summary
We found 2 recent headlines mentioning Aktis Oncology (AKTS): 0 in the past week and 2 in the past 30 days, most often from Seeking Alpha, GlobeNewswire. For price context, AKTS is down 1.52% at $16.15. The most recent story, "Aktis Oncology reports Q3 results", was published by Seeking Alpha on Nov 12, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Aktis Oncology headlines
- Aktis Oncology reports Q3 resultsSeeking Alpha
- Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial ProgressBOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted…GlobeNewswire